Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 76, Issue 4, 2015, Pages 440-446

  Foa, Edna B ^a   Simpson, Helen Blair ^b,c   Rosenfield, David ^d   Liebowitz, Michael R ^c   Cahill, Shawn P ^f   Huppert, Jonathan D ^a,g   Bender, James ^b   McLean, Carmen P ^a   Maher, Michael J ^b   Campeas, Raphael ^b,c   Hahn, Chang Gyu ^a   Imms, Patricia ^a   Pinto, Anthony ^b,c   Powers, Mark B ^e   Rodriguez, Carolyn I ^b,c   Van Meter, Page E ^b   Vermes, Donna ^b   Williams, Monnica T ^h  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Department of Medicine   (United States)

^d SOUTHERN METHODIST UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^g HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^h UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ADULT; AGED; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG POTENTIATION; DRUG RESPONSE; DSM-IV; EXPOSURE AND RESPONSE PREVENTION; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; YALE BROWN OBSESSIVE COMPULSIVE SCALE; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; IMPLOSIVE THERAPY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOLOGY; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMPLOSIVE THERAPY; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS; UNITED STATES; YOUNG ADULT;

EID: 84932102598     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14m09044     Document Type: Article

References (35)

1. Wang PS, Sherrill J, Vitiello B. Unmet need for services and interventions among adolescents with mental disorders. Am J Psychiatry. 2007;164(1):1-3. PubMed
2. Simpson HB, Huppert JD, Petkova E, et al. Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(2):269-276. doi:10.408/JCP.v67n0214 PubMed
3. Tolin DF, Maltby N, Diefenbach GJ, et al. Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: A wait-listcontrolled open trial. J Clin Psychiatry. 2004;65(7):922-931. doi:10.408/JCP.v65n0708 PubMed
4. Kampman M, Keijsers GP, Hoogduin CA, et al. Addition of cognitivebehaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychiatr Scand. 2002;106(4):314-319. doi:10.1034/j.160-047.202.01261.x PubMed
5. Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessivecompulsive disorder. Am J Psychiatry. 2008;165(5):621-630. doi:10.176/api.ajp.207.0709140 PubMed
6. Tenneij NH, van Megen HJ, Denys DA, et al. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry. 2005;66(9):1169-1175. doi:10.408/JCP.v6n0913 PubMed
7. Tundo A, Salvati L, Busto G, et al. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: A naturalistic study. J Clin Psychiatry. 2007;68(10):1552-1556. doi:10.408/JCP.v68n1013 PubMed
8. Foa EB, Simpson HB, Liebowitz MR, et al. Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder. J Clin Psychiatry. 2013;74(5):464-469. doi:10.408/JCP.12m08017 PubMed
9. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622-632. doi:10.1038/sj.mp.401823 PubMed
10. Dold M, Aigner M, Lanzenberger R, et al. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2013;16(3):557-574. PubMed
11. Matsunaga H, Nagata T, Hayashida K, et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRIrefractory obsessive-compulsive disorder. J Clin Psychiatry. 2009;70(6):863-868. doi:10.408/JCP.08m04369 PubMed
12. Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessivecompulsive disorder: A randomized clinical trial. JAMA Psychiatry; 2013;70(11):1190-1199. PubMed
13. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 2: validity. Arch Gen Psychiatry. 1989;46(11):1012-1016. doi:10.101/archpsyc.1989.01810105408 PubMed
14. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011. doi:10.101/archpsyc.1989.01810104807 PubMed
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
16. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSMIV Axis I Disorders-Patient Edition. New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1996.
17. Kozak MJ, Foa EP. Mastery of Obsessive-Compulsive Disorder. Boulder, CO: Graywind Publications Incorporated; 1997.
18. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebocontrolled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57(8):794-801. doi:10.101/archpsyc.57.8.794 PubMed
19. Erzegovesi S, Guglielmo E, Siliprandi F, et al. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: A double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005;15(1):69-74. doi:10.1016/j.euroneuro.204.04.04 PubMed
20. Hollander E, Baldini Rossi N, Sood E, et al. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: A double-blind, placebocontrolled study. Int J Neuropsychopharmacol. 2003;6(4):397-401. doi:10.1017/S14614570303730 PubMed
21. Eisen JL, Phillips KA, Baer L, et al. The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry. 1998;155(1):102-108. PubMed
22. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull. 1993;29(2):321-326. PubMed
23. Weissman MM, Bothwell S. Assessment of social adjustment by patient selfreport. Arch Gen Psychiatry. 1976;33(9):1111-1115. doi:10.101/archpsyc.1976.017090101010 PubMed
24. Foa EB, Huppert JD, Leiberg S, et al. The Obsessive-Compulsive Inventory: development and validation of a short version. Psychol Assess. 2002;14(4):485-496. doi:10.1037/1040-3590.14.4.485 PubMed
25. Levine J, Schooler NR. SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22(2):343-381. PubMed
26. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989;28(4):566-573. doi:10.1097/04583-1989070-015 PubMed
27. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(S212):11-19. doi:10.1/j.160-047.1970.tb0206.x PubMed
28. Barnes TR. The Barnes Akathisia Rating Scale-revisited. J Psychopharmacol. 2003;17(4):365-370. doi:10.17/02698103174013 PubMed
29. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health;1976:534-537.
30. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988;39(11):1172-1177. PubMed
31. Hedeker D, Gibbons RD. Longitudinal Data Analysis. Hoboken, NJ: John Wiley & Sons; 2006.
32. Maas CJM and Hox JJ. Sufficient sample sizes for multilevel modeling. Methodol Eur J Res Methods Behav Soc Sci. 2005;1(3):86-92. doi:10.1027/1614-241.1.3.86
33. Singer JD, Willett JB. Applied Longitudinal Data Analysis. New York, NY: Oxford University Press; 2003. doi:10.1093/acprof:oso/9780195152968.01.01
34. Van Oppen P, Hoekstra RJ, Emmelkamp PM. The structure of obsessivecompulsive symptoms. Behav Res Ther. 1995;33(1):15-23. doi:10.1016/05-7967(94)E010-G PubMed
35. Whittal ML, Robichaud M, Thordarson DS, et al. Group and individual treatment of obsessive-compulsive disorder using cognitive therapy and exposure plus response prevention: A 2-year follow-up of two randomized trials. J Consult Clin Psychol. 2008;76(6):1003-1014.